Chipotle 2009 Annual Report Download - page 71

Download and view the complete annual report

Please find page 71 of the 2009 Chipotle annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 112

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112

Class II directors whose terms expire at the 2010
annual meeting of shareholders and who are nominees
for terms expiring at the 2013 annual meeting Age
Director
Since
Neil W. Flanzraich ........................ Mr.Flanzraich has been a private investor
since February 2006. From 1998 through its
sale in January 2006 to TEVA
Pharmaceuticals Industries, Ltd., he served as
Vice Chairman and President of IVAX
Corporation, an international pharmaceutical
company. From 1995 to 1998, Mr. Flanzraich
served as Chairman of the Life Sciences Legal
Practice Group of Heller Ehrman LLP, a law
firm, and from 1981 to 1994, served in
various capacities at Syntex Corporation, a
pharmaceutical company. Mr. Flanzraich’s
past executive experience helped him develop
outstanding skills in leading and managing
strong teams of employees, and in oversight
of the growth and financing of businesses in a
rapidly-evolving market. His legal
background also is valuable to us in the risk
management area, and Mr. Flanzraich brings
to us extensive experience serving as an
independent director of other companies. He
is also a director of Continucare Corporation
(NYSE Amex:CNU), Equity One Inc.
(NYSE:EQY), Javelin Pharmaceuticals, Inc.
(NYSE Amex:JAV), and BELLUS Health
Inc. (TSX:BLUS). Mr. Flanzraich was a
director of RAE Systems, Inc. until March
2009, a director of IVAX Diagnostics, Inc.
until April 2006, and a director of IVAX
Corporation until January 2006.
Mr. Flanzraich received an A.B. from Harvard
College and a J.D. from Harvard Law School.
66 2007
Darlene J. Friedman ....................... Prior to retiring in 1995, Ms. Friedman spent
19 years at Syntex Corporation where she
held a variety of management positions, most
recently as Senior Vice President of Human
Resources. While at Syntex Corporation,
Ms. Friedman was a member of the corporate
executive committee and the management
committee, and was responsible for the
analysis, recommendation and administration
of the company’s executive compensation
programs and worked directly with the
compensation committee of Syntex’s board.
This experience and Ms. Friedman’s talent in
these areas are invaluable in connection with
her service as a director and as a member of
our Compensation Committee. Ms. Friedman
holds a Bachelor of Arts degree in psychology
from the University of California at Berkeley
and an MBA from the University of Colorado.
67 1995
7
Proxy Statement